---
schema_version: "secwatch.filing_event.v1"
accession: "0001601830-24-000165"
form_type: "8-K"
ticker: "RXRX"
cik: "0001601830"
company_name: "RECURSION PHARMACEUTICALS, INC."
filed_at: "2024-10-02T23:59:59+00:00"
generated_at: "2026-05-30T22:34:06.253438+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.65
calibrated_materiality_score: 0.65
confidence: "high"
source: SEC EDGAR
---

# FDA clears IND for Recursion's REC-1245, a first-in-class RBM39 degrader for solid tumors/lymphoma

## Summary
- FDA cleared IND for REC-1245, a potential first-in-class RBM39 degrader for biomarker-enriched solid tumors and lymphoma.
- Phase 1/2 trial to start Q4 2024 evaluating safety, tolerability, PK/PD, and monotherapy efficacy.
- Target identified via Recursion's AI platform; program advanced from target to IND in under 18 months.
- Initially addressable population estimated at >100,000 patients in the US and EU5.
- Preclinical data show RBM39 degradation induces splicing defects downregulating DNA Damage Response networks.

## SEC filing metadata
- accession: 0001601830-24-000165
- form_type: 8-K
- ticker: RXRX
- cik: 0001601830
- company_name: RECURSION PHARMACEUTICALS, INC.
- filed_at: 2024-10-02T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.65
- calibrated_materiality_score: 0.65
- confidence: high
- sec_items: 7.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/0001601830-24-000165-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1601830/000160183024000165/rxrx-20241002.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001601830-24-000165
- JSON: https://secwatch.observer/filing/0001601830-24-000165.json
- Plain text: https://secwatch.observer/filing/0001601830-24-000165.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.